Gangadhar TC, et al. - KEYNOTE-030 was a global expanded access program that allowed access to pembrolizumab, an antiprogrammed death 1 antibody, for patients with advanced melanoma before its regulatory approval. Findings of this investigation demonstrated that safety and efficacy displayed by pembrolizumab in this expanded access program were consistent with those previously reported for similar populations. Furthermore, findings supported the use of pembrolizumab for patients with advanced melanoma.